{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:53:19Z","timestamp":1786989199132,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hallucinogen persisting perception disorder (HPPD) is characterized by the re-emergence of perceptual symptoms experienced during acute hallucinogen intoxication following drug cessation. The underlying pathophysiology is poorly understood. We report the clinical characteristics and investigation findings of a series of HPPD cases with a literature review of previous case reports. We draw parallels between the features of HPPD and Visual Snow Syndrome (VSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective case series of 13 patients referred from neuro-ophthalmologists. Literature review with 24 HPPD case reports were identified through database search using the terms \u201challucinogenic persisting perception disorder\u201d OR \u201challucinogen persisting perception disorder.\u201d<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lysergic acid diethylamide (LSD), 3,4-Methyl enedioxy methamphetamine (MDMA) and cannabinoid use was common. Cannabinoids and MDMA were mostly used in association with classical hallucinogens. The most frequent symptoms in our patients were visual snow, floaters, palinopsia, photophobia and nyctalopia. In the literature other symptoms included visual hallucinations altered motion perception, palinopsia, tracers and color enhancement. Ophthalmic and neurologic investigations were mostly normal. The majority of patients had ongoing symptoms. Two of our patients fully recovered\u2014one after treatment with benzodiazepine and one without treatment. Twenty-five percent of cases from the literature fully recovered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HPPD presents with heterogeneous visual phenomena on a background of previous classic and non-classic hallucinogen use. Ophthalmic investigations are typically normal. The symptoms of HPPD in our case series overlap with the typical features of Visual Snow Syndrome (VSS). Patients presenting with VSS should be screened for past recreational drug use. The DSM-5 description of HPPD does not include visual snow, nyctalopia, photophobia or floaters. A revision of the diagnostic criteria to include these symptoms may better reflect the typical clinical phenotype. Increased awareness of HPPD as a secondary cause of VSS can avoid extensive investigations. Controlled trials comparing primary and secondary VSS patients are needed to understand the pathophysiology better and optimize treatment for HPPD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.878609","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T04:48:55Z","timestamp":1651812535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Hannah","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare L.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Solly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Clough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Van Der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1360-0443.1993.tb02018.x","article-title":"Adverse consequences of lysergic acid diethylamide","volume":"88","author":"Abraham","year":"1993","journal-title":"Addiction."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume-title":"Brain Sci.","author":"Martinotti","year":"2018"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"Association","year":"2013"},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0925-4927(01)00098-1","article-title":"EEG coherence in post-LSD visual hallucinations","volume":"107","author":"Abraham","year":"2001","journal-title":"Psychiatry Res."},{"key":"B5","first-page":"296","article-title":"Flashbacks and HPPD: a clinical-oriented concise review","volume":"51","author":"A","year":"2014","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pbr.2018.09.013","article-title":"An introduction to psychedelic neuroscience","volume":"242","author":"Calvey","year":"2018","journal-title":"Prog Brain Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1021\/acschemneuro.8b00615","article-title":"DARK classics in chemical neuroscience: atropine, scopolamine, and other anticholinergic deliriant hallucinogens","volume":"10","author":"Lakstygal","year":"2019","journal-title":"ACS Chem Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1176\/ajp.128.2.213","article-title":"Hallucinogenic effects of marijuana as currently used","volume":"128","author":"Keeler","year":"1971","journal-title":"Am J Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/s-2003-38173","article-title":"Persisting visual hallucinations and illusions in previously drug-addicted patients","volume":"220","author":"Gaillard","year":"2003","journal-title":"Klin Monbl Augenheilkd."},{"key":"B11","first-page":"277","article-title":"Synthetic cannabis substances (SPS) use and hallucinogen persisting perception disorder (HPPD): two case reports","volume":"51","author":"Lerner","year":"2014","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"B12","volume-title":"Psychedelic Drugs Reconsidered","author":"Grinspoon","year":"1979"},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugalcdep.2010.09.006","article-title":"Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire","volume":"114","author":"Baggott","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"B14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","article-title":"Hallucinogen persisting perception disorder: what do we know after 50 years?","volume":"69","author":"Halpern","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"B15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_457","article-title":"A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD","volume":"36","author":"Halpern","year":"2018","journal-title":"Curr Top Behav Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/121.10.1819","article-title":"Complex visual hallucinations. Clinical and neurobiological insights","volume":"121","author":"Manford","year":"1998","journal-title":"Brain."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1212\/WNL.0000000000008909","article-title":"Visual snow syndrome: a clinical and phenotypical description of 1,100 cases","volume":"94","author":"Puledda","year":"2020","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/2045125312451270","article-title":"Hallucinogen-persisting perception disorder","volume":"2","author":"Hermle","year":"2012","journal-title":"Ther Adv Psychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e4077","DOI":"10.7759\/cureus.4077","article-title":"Hallucinogen-persisting perception disorder in a 21-year-old Man","volume":"11","author":"Kurtom","year":"2019","journal-title":"Cureus."},{"key":"B20","first-page":"67","article-title":"LSD-associated \u201cAlice in Wonderland Syndrome (AIWS)\u201d: a Hallucinogen Persisting Perception Disorder (HPPD) case report","volume":"52","author":"Lerner","year":"2015","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/10550887.2019.1673655","article-title":"Hallucinogen persisting perception disorder: a literature review and three case reports","volume":"37","author":"Skryabin","year":"2018","journal-title":"J Addict Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/0897190014566314","article-title":"Hallucinogen persisting perception disorder and risk of suicide","volume":"29","author":"Brodrick","year":"2016","journal-title":"J Pharm Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/ipm.2013.59","article-title":"Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report","volume":"31","author":"Subramanian","year":"2014","journal-title":"Ir J Psychol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00004714-200106000-00016","article-title":"Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report","volume":"21","author":"Aldurra","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"B25","first-page":"100","article-title":"LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report","volume":"39","author":"Lerner","year":"2002","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"B26","first-page":"748","volume":"56","author":"Neven","year":"2014","journal-title":"Tijdschr Psychiatr."},{"key":"B27","first-page":"133","article-title":"LSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports","volume":"38","author":"Lerner","year":"2001","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1039856217726694","article-title":"The trip of a lifetime: hallucinogen persisting perceptual disorder","volume":"26","author":"Anderson","year":"2018","journal-title":"Australas Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/00006982-200410000-00022","article-title":"Persistent afterimages (palinopsia) and photophobia in a patient with a history of LSD use","volume":"24","author":"Sunness","year":"2004","journal-title":"Retina."},{"key":"B30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/13554790903329141","article-title":"A case of persistent visual hallucinations of faces following LSD abuse: a functional Magnetic Resonance Imaging study","volume":"16","author":"Iaria","year":"2010","journal-title":"Neurocase."},{"key":"B31","first-page":"307","article-title":"LSD flashbacks - the appearance of new visual imagery not experienced during initial intoxication: Two Case Reports","volume":"51","author":"Lerner","year":"2014","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/JCP.0000000000000966","article-title":"Hallucinogen Persisting perception disorder after ibogaine treatment for opioid dependence","volume":"38","author":"Knuijver","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/02791072.2017.1316431","article-title":"JWH-122 consumption adverse effects: a case of hallucinogen persisting perception disorder five-year follow-up","volume":"49","author":"Coppola","year":"2017","journal-title":"J Psychoactive Drugs."},{"key":"B34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/WCO.0000000000000523","article-title":"Visual snow syndrome: what we know so far","volume":"31","author":"Puledda","year":"2018","journal-title":"Curr Opin Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1212\/WNL.0000000000007825","article-title":"Treatment effects and comorbid diseases in 58 patients with visual snow","volume":"93","author":"van Dongen","year":"2019","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2020-318653","article-title":"Evaluation of treatment response and symptom progression in 400 patients with visual snow syndrome","volume-title":"Br J Ophthalmol.","author":"Puledda","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/WCO.0000000000000768","article-title":"Visual snow syndrome: a review on diagnosis, pathophysiology, and treatment","volume":"33","author":"Traber","year":"2020","journal-title":"Curr Opin Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.878609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T04:49:03Z","timestamp":1651812543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.878609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":37,"alternative-id":["10.3389\/fneur.2022.878609"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.878609","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"article-number":"878609"}}